CAM
CABA icon

Cormorant Asset Management’s Cabaletta Bio CABA Stock Holding History

Cormorant Asset Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Buy
5,500,000
+1,100,000
+25% +$3.05M 0.74% 32
2025
Q4 		$9.64M Sell
4,400,000
-600,000
-12% -$1.49M 0.45% 30
2025
Q3 		$11.7M Hold
5,000,000
– – 0.81% 29
2025
Q2 		$7.6M Buy
+5,000,000
New +$7.8M 0.57% 32
2024
Q2 		– Sell
-1,100,000
Closed -$18.8M – 57
2024
Q1 		$18.8M Buy
+1,100,000
New +$23.6M 0.82% 34
2023
Q4 		– Sell
-2,879,424
Closed -$43.8M – 49
2023
Q3 		$43.8M Buy
2,879,424
+657,685
+30% +$8.99M 2.56% 12
2023
Q2 		$28.7M Buy
2,221,739
+400,000
+22% +$4.34M 1.61% 16
2023
Q1 		$15.1M Sell
1,821,739
-150,000
-8% -$1.4M 0.99% 28
2022
Q4 		$18.2M Buy
1,971,739
+817,315
+71% +$2.98M 1.22% 28
2022
Q3 		$750K Hold
1,154,424
– – 0.05% 66
2022
Q2 		$1.22M Hold
1,154,424
– – 0.09% 67
2022
Q1 		$2.34M Hold
1,154,424
– – 0.18% 62
2021
Q4 		$4.38M Sell
1,154,424
-457,199
-28% -$4.88M 0.26% 56
2021
Q3 		$19.6M Hold
1,611,623
– – 0.8% 36
2021
Q2 		$13.9M Sell
1,611,623
-292,801
-15% -$2.88M 0.47% 50
2021
Q1 		$21.1M Hold
1,904,424
– – 0.47% 48
2020
Q4 		$23.8M Sell
1,904,424
-162,878
-8% -$2.11M 0.57% 42
2020
Q3 		$22.4M Sell
2,067,302
-38,542
-2% -$443K 0.86% 37
2020
Q2 		$23.5M Sell
2,105,844
-2
-0% -$15 0.9% 36
2020
Q1 		$15.4M Sell
2,105,846
-13,286
-0.6% -$182K 0.71% 40
2019
Q4 		$29.6M Buy
+2,119,132
New +$25.1M 1.18% 29

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cormorant Asset Management's CABA Position: Q1 2026 in Review

Cormorant Asset Management increased its Cabaletta Bio (CABA) stake by 25% in Q1 2026, buying an estimated $3.05M and bringing the position to 5,500,000 shares worth $14.8M. The position accounts for 0.74% of the portfolio, ranked #32.

Cormorant Asset Management first reported a position in CABA in Q4 2019 and has held it in 21 quarters since. The position peaked at $43.8M in Q3 2023. 108 funds tracked by Wall St. Rank hold CABA as of Q1 2026.

  • Cormorant Asset Management held 5,500,000 shares of Cabaletta Bio worth $14.8M as of Q1 2026.
  • Cormorant Asset Management bought 1,100,000 Cabaletta Bio shares in Q1 2026, an estimated $3.05M.
  • Cabaletta Bio made up 0.74% of Cormorant Asset Management's portfolio in Q1 2026, its #32 holding.
  • Cormorant Asset Management first reported a position in Cabaletta Bio in Q4 2019 and has held it in 21 quarters since.
  • Cormorant Asset Management's Cabaletta Bio position peaked at $43.8M in Q3 2023.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.